- Home
- WWR vs SERA Comparison
WWR vs SERA Comparison
Compare WWR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WWR | SERA |
|---|---|---|
| Founded | 1977 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Precision Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.3M | 107.3M |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WWR | SERA |
|---|---|---|
| Price | $0.80 | $1.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.88 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 23.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.45 | $1.37 |
| 52 Week High | $3.75 | $4.35 |
Technical Indicators
Market Signals| Indicator | WWR | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 37.13 | 22.36 |
| Support Level | $0.66 | $1.37 |
| Resistance Level | $0.83 | $2.00 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 1.36 | 1.77 |
Price Performance
Historical ComparisonAbout WWR Westwater Resources Inc.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.